

Jeanette H W Leusen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9566630/publications.pdf>

Version: 2024-02-01

126
papers

5,354
citations

76294

40
h-index

102432

66
g-index

131
all docs

131
docs citations

131
times ranked

7192
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure. <i>OncImmunology</i> , 2022, 11, 2033528.	2.1	19
2	Evaluation of immunotherapies improving macrophage anti-tumor response using a microfluidic model. <i>Organs-on-a-Chip</i> , 2022, 4, 100019.	1.8	7
3	Analysing the protection from respiratory tract infections and allergic diseases early in life by human milk components: the PRIMA birth cohort. <i>BMC Infectious Diseases</i> , 2022, 22, 152.	1.3	1
4	Fc gamma receptor is not required for in vivo processing of radio- and drug-conjugates of the dead tumor cell-targeting monoclonal antibody, APOMABA®. <i>Biomedicine and Pharmacotherapy</i> , 2022, 151, 113090.	2.5	0
5	Targeting the high affinity receptor, FcγRI, in autoimmune disease, neuropathy, and cancer. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	6
6	Complement receptor 3 mediates both sinking phagocytosis and phagocytic cup formation via distinct mechanisms. <i>Journal of Biological Chemistry</i> , 2021, 296, 100256.	1.6	22
7	Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions. <i>Cancer Science</i> , 2021, 112, 3029-3040.	1.7	11
8	Novel oncolytic adenovirus expressing enhanced cross-hybrid IgG A Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids. , 2021, 9, e003000.		27
9	The selection of variable regions affects effector mechanisms of IgA antibodies against CD20. <i>Blood Advances</i> , 2021, 5, 3807-3820.	2.5	9
10	Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn<i>in vitro</i>and<i>in vivo</i>. <i>MAbs</i> , 2021, 13, 1893888.	2.6	16
11	Anti-CD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma. , 2021, 9, e003163.		11
12	Complement receptor 3 mediates both sinking phagocytosis and phagocytic cup formation via distinct mechanisms. <i>Journal of Biological Chemistry</i> , 2021, , .	1.6	0
13	IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47â€“SIRP± Checkpoint Inhibition. <i>Cancer Immunology Research</i> , 2020, 8, 120-130.	1.6	57
14	Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies. <i>MAbs</i> , 2020, 12, 1795505.	2.6	13
15	Bovine IgG Prevents Experimental Infection With RSV and Facilitates Human T Cell Responses to RSV. <i>Frontiers in Immunology</i> , 2020, 11, 1701.	2.2	13
16	Bivalent binding on cells varies between anti-CD20 antibodies and is dose-dependent. <i>MAbs</i> , 2020, 12, 1792673.	2.6	14
17	Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents. <i>Antibodies</i> , 2020, 9, 70.	1.2	32
18	Î³9Î²T cell diversity and the receptor interface with tumor cells. <i>Journal of Clinical Investigation</i> , 2020, 130, 4637-4651.	3.9	49

#	ARTICLE	IF	CITATIONS
19	Breast Milk Prefusion F Immunoglobulin G as a Correlate of Protection Against Respiratory Syncytial Virus Acute Respiratory Illness. <i>Journal of Infectious Diseases</i> , 2019, 219, 59-67.	1.9	42
20	Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering. <i>Science Advances</i> , 2019, 5, eaaw1822.	4.7	13
21	Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG. <i>Frontiers in Immunology</i> , 2019, 10, 704.	2.2	95
22	Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRP α axis and a target for cancer immunotherapy. <i>Nature Medicine</i> , 2019, 25, 612-619.	15.2	156
23	Fc γ RI Dynamics Are Regulated by GSK-3 and PKC η During Cytokine Mediated Inside-Out Signaling. <i>Frontiers in Immunology</i> , 2019, 9, 3191.	2.2	13
24	Identification of a tumor-specific allo-HLA α -restricted β TCR. <i>Blood Advances</i> , 2019, 3, 2870-2882.	2.5	28
25	CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 134-142.	0.7	82
26	Immune Effector Functions of Human IgG2 Antibodies against EGFR. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 75-88.	1.9	22
27	New insights in Type I and α II CD20 antibody mechanisms of action with a panel of novel α CD20 antibodies. <i>British Journal of Haematology</i> , 2018, 180, 808-820.	1.2	51
28	Comment on "Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells". <i>Journal of Immunology</i> , 2018, 200, 2515-2516.	0.4	3
29	Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo. <i>MAbs</i> , 2018, 10, 453-462.	2.6	17
30	Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody α -dependent cell α -mediated cytotoxicity and complement α -dependent cytotoxicity. <i>British Journal of Haematology</i> , 2018, 181, 413-417.	1.2	33
31	Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis. <i>Cell Reports</i> , 2018, 23, 3946-3959.e6.	2.9	245
32	Mechanisms of inside-out signaling of the high-affinity IgG receptor Fc γ RI. <i>Science Signaling</i> , 2018, 11, .	1.6	28
33	Effects of Bovine Immunoglobulins on Immune Function, Allergy, and Infection. <i>Frontiers in Nutrition</i> , 2018, 5, 52.	1.6	109
34	The latest developments with anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 973-982.	1.4	7
35	DC subset α -specific induction of T cell responses upon antigen uptake via Fc γ 3 receptors in vivo. <i>Journal of Experimental Medicine</i> , 2017, 214, 1509-1528.	4.2	53
36	Single Nucleotide Polymorphisms of the High Affinity IgG Receptor Fc γ RI Reduce Immune Complex Binding and Downstream Effector Functions. <i>Journal of Immunology</i> , 2017, 199, 2432-2439.	0.4	8

#	ARTICLE	IF	CITATIONS
37	Human amniotic fluid antibodies protect the neonate against respiratory syncytial virus infection. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1477-1480.e5.	1.5	9
38	Clarifying the Confusion between Cytokine and Fc Receptor α -Common Gamma Chain. <i>Immunity</i> , 2016, 45, 225-226.	6.6	37
39	MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL. <i>Cell Death and Disease</i> , 2016, 7, e2345-e2345.	2.7	53
40	Human IgG1 antibodies suppress angiogenesis in a target-independent manner. <i>Signal Transduction and Targeted Therapy</i> , 2016, 1, .	7.1	30
41	Intravenous immune globulin suppresses angiogenesis in mice and humans. <i>Signal Transduction and Targeted Therapy</i> , 2016, 1, .	7.1	23
42	The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fc β Receptor α -Mediated Cross-Linking. <i>Journal of Immunology</i> , 2016, 197, 807-813.	0.4	225
43	An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement <i>In Vivo</i> . <i>Cancer Research</i> , 2016, 76, 403-417.	0.4	57
44	A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA. <i>MAbs</i> , 2016, 8, 74-86.	2.6	39
45	Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting. <i>MAbs</i> , 2016, 8, 87-98.	2.6	47
46	CD20 Antibodies of Human IgA Isotype Mediate CDC, and ADCC By Myeloid Effector Cells. <i>Blood</i> , 2016, 128, 1835-1835.	0.6	2
47	Fc receptor inside α ut signaling and possible impact on antibody therapy. <i>Immunological Reviews</i> , 2015, 268, 74-87.	2.8	46
48	Targeted Delivery of a Sialic Acid-Blocking Glycomimetic to Cancer Cells Inhibits Metastatic Spread. <i>ACS Nano</i> , 2015, 9, 733-745.	7.3	123
49	Meeting Report on Immunoreceptors 2014. <i>FASEB Journal</i> , 2015, 29, 740-744.	0.2	1
50	Simultaneous Targeting of Fc β Rs and Fc \pm RI Enhances Tumor Cell Killing. <i>Cancer Immunology Research</i> , 2015, 3, 1316-1324.	1.6	40
51	IgA as therapeutic antibody. <i>Molecular Immunology</i> , 2015, 68, 35-39.	1.0	52
52	Recombinant Soluble Respiratory Syncytial Virus F Protein That Lacks Heptad Repeat B, Contains a GCN4 Trimerization Motif and Is Not Cleaved Displays Prefusion-Like Characteristics. <i>PLoS ONE</i> , 2015, 10, e0130829.	1.1	15
53	Pharmacokinetics and myeloid effector cell engagement of an engineered IgA antibody against the epidermal growth factor receptor.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3037-3037.	0.8	0
54	Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. <i>MAbs</i> , 2014, 6, 1133-1144.	2.6	86

#	ARTICLE	IF	CITATIONS
55	Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies. <i>MAbs</i> , 2014, 6, 1300-1313.	2.6	16
56	Fc γ 3-Chain ITAM Signaling Is Critically Required for Cross-Presentation of Soluble Antibody-Antigen Complexes by Dendritic Cells. <i>Journal of Immunology</i> , 2014, 193, 5506-5514.	0.4	28
57	Anti-tumor activity of human IgG1 anti-gp75 TA99 mAb against B16F10 melanoma in human Fc γ RI transgenic mice. <i>Immunology Letters</i> , 2014, 160, 151-157.	1.1	12
58	A novel Fc γ RIIIa Q27W gene variant is associated with common variable immune deficiency through defective Fc γ RIIIa downstream signaling. <i>Clinical Immunology</i> , 2014, 155, 108-117.	1.4	15
59	Fc γ receptor IIIA genotype is associated with rituximab response in antimyelin-associated glycoprotein neuropathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 918-920.	0.9	16
60	Inhibition of the Classical and Lectin Pathway of the Complement System by Recombinant LAIR-2. <i>Journal of Innate Immunity</i> , 2014, 6, 284-292.	1.8	20
61	Specificity and Effector Functions of Human RSV-Specific IgG from Bovine Milk. <i>PLoS ONE</i> , 2014, 9, e112047.	1.1	33
62	The Role of IgG in Immune Responses. , 2013, , 85-112.		1
63	IgG Antibodies in Food Allergy Influence Allergen-Antibody Complex Formation and Binding to B Cells: A Role for Complement Receptors. <i>Journal of Immunology</i> , 2013, 191, 3526-3533.	0.4	26
64	Correction: Cutting Edge: Fc γ RIII (CD16) and Fc γ RI (CD64) Are Responsible for Anti-Glycoprotein 75 Monoclonal Antibody TA99 Therapy for Experimental Metastatic B16 Melanoma. <i>Journal of Immunology</i> , 2013, 190, 1381-1381.	0.4	0
65	<i>Staphylococcus aureus</i> Formyl Peptide Receptor-like 1 Inhibitor (FLIPr) and Its Homologue FLIPr-like Are Potent Fc γ RIII Antagonists That Inhibit IgG-Mediated Effector Functions. <i>Journal of Immunology</i> , 2013, 191, 353-362.	0.4	46
66	IgG AEGFR antibodies mediate tumour killing <i>in vivo</i> . <i>EMBO Molecular Medicine</i> , 2013, 5, 1213-1226.	3.3	107
67	Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2 m(1) antibody. <i>MAbs</i> , 2013, 5, 936-945.	2.6	16
68	Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. <i>Blood</i> , 2013, 122, 3482-3491.	0.6	206
69	Glycoengineered CD20 Antibody Obinutuzumab Activates Neutrophils and Mediates Phagocytosis Through CD16B More Efficiently Than Rituximab. <i>Blood</i> , 2013, 122, 4419-4419.	0.6	0
70	Cutting Edge: Fc γ RIII (CD16) and Fc γ RI (CD64) Are Responsible for Anti-Glycoprotein 75 Monoclonal Antibody TA99 Therapy for Experimental Metastatic B16 Melanoma. <i>Journal of Immunology</i> , 2012, 189, 5513-5517.	0.4	34
71	Crosstalk between Human IgG Isotypes and Murine Effector Cells. <i>Journal of Immunology</i> , 2012, 189, 3430-3438.	0.4	180
72	Characterization of a Mutated IgA2 Antibody of the m(1) Allotype against the Epidermal Growth Factor Receptor for the Recruitment of Monocytes and Macrophages. <i>Journal of Biological Chemistry</i> , 2012, 287, 25139-25150.	1.6	44

#	ARTICLE	IF	CITATIONS
73	Boosting antibody therapy with complement. <i>Blood</i> , 2012, 119, 5945-5947.	0.6	9
74	Patients with unstable angina pectoris show an increased frequency of the Fc gamma RIIa R131 allele. <i>Autoimmunity</i> , 2012, 45, 556-564.	1.2	10
75	Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice. <i>Immunology Letters</i> , 2012, 143, 44-52.	1.1	39
76	Daratumumab, a Human CD38 Antibody Induces Apoptosis of Myeloma Tumor Cells Via Fc Receptor-Mediated Crosslinking.. <i>Blood</i> , 2012, 120, 2974-2974.	0.6	24
77	Mechanisms of action of CD20 antibodies. <i>American Journal of Cancer Research</i> , 2012, 2, 676-90.	1.4	88
78	The Fc γ 3 receptor IIA R131H gene polymorphism is associated with endothelial function in patients with hypercholesterolaemia. <i>Atherosclerosis</i> , 2011, 218, 411-415.	0.4	10
79	The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. <i>Haematologica</i> , 2011, 96, 1822-1830.	1.7	69
80	Functional Characteristics of the High Affinity IgG Receptor, Fc γ 3RI. <i>Journal of Immunology</i> , 2011, 186, 2699-2704.	0.4	152
81	Recombinant Dimeric IgA Antibodies against the Epidermal Growth Factor Receptor Mediate Effective Tumor Cell Killing. <i>Journal of Immunology</i> , 2011, 186, 3770-3778.	0.4	62
82	Expression of CD64 (Fc γ 3RI) in skin of patients with acute GVHD. <i>Bone Marrow Transplantation</i> , 2011, 46, 1566-1569.	1.3	2
83	Contribution of Classic and Alternative Effector Pathways in Peanut-Induced Anaphylactic Responses. <i>PLoS ONE</i> , 2011, 6, e28917.	1.1	52
84	Cytokine-induced immune complex binding to the high-affinity IgG receptor, Fc γ 3RI, in the presence of monomeric IgG. <i>Blood</i> , 2010, 116, 5327-5333.	0.6	54
85	c-Jun activating binding protein 1 binds to the IgA receptor and modulates protein levels of Fc γ 1RI and Fc γ 3 chain. <i>European Journal of Immunology</i> , 2010, 40, 2035-2040.	1.6	8
86	<i>In vivo</i> Cytotoxicity of Type I CD20 Antibodies Critically Depends on Fc Receptor ITAM Signaling. <i>Cancer Research</i> , 2010, 70, 3209-3217.	0.4	125
87	Serum Antibodies Critically Affect Virus-Specific CD4+/CD8+ T Cell Balance during Respiratory Syncytial Virus Infections. <i>Journal of Immunology</i> , 2010, 185, 6489-6498.	0.4	31
88	Recombinant Dimeric IgA Antibodies as Tumor-Specific Agents.. <i>Blood</i> , 2010, 116, 1488-1488.	0.6	0
89	Biological Validation of Plant-derived Anti-human Colorectal Cancer Monoclonal Antibody CO17-1A. <i>Hybridoma</i> , 2009, 28, 7-12.	0.5	8
90	Association of the leukocyte immunoglobulin G (Fc γ 3) receptor IIIa ϵ 158V/F polymorphism with inflammatory myopathies in Dutch patients. <i>Tissue Antigens</i> , 2009, 73, 586-589.	1.0	5

#	ARTICLE	IF	CITATIONS
91	OS9 interacts with DC-STAMP and modulates its intracellular localization in response to TLR ligation. <i>Molecular Immunology</i> , 2009, 46, 505-515.	1.0	22
92	Fc γ RIIIa genotype is associated with acute coronary syndromes as first manifestation of coronary artery disease. <i>Atherosclerosis</i> , 2009, 205, 512-516.	0.4	24
93	Fc γ RI (CD64) resides constitutively in lipid rafts. <i>Immunology Letters</i> , 2008, 116, 149-155.	1.1	30
94	Protein 4.1G binds to a unique motif within the Fc γ RI cytoplasmic tail. <i>Molecular Immunology</i> , 2008, 45, 2069-2075.	1.0	14
95	Filamin A Stabilizes Fc γ RI Surface Expression and Prevents Its Lysosomal Routing. <i>Journal of Immunology</i> , 2008, 180, 3938-3945.	0.4	35
96	Inside-Out Regulation of Fc γ RI (CD89) Depends on PP2A. <i>Journal of Immunology</i> , 2008, 181, 4080-4088.	0.4	27
97	Fc γ RI-Chain Dependent Signaling in Immature Neutrophils Is Mediated by Fc γ RI, but Not by Fc γ RI. <i>Journal of Immunology</i> , 2007, 179, 2918-2924.	0.4	24
98	The Importance of Human Fc γ RI in Mediating Protection to Malaria. <i>PLoS Pathogens</i> , 2007, 3, e72.	2.1	95
99	Direct targeting of genetically modified tumour cells to Fc γ RI triggers potent tumour cytotoxicity. <i>British Journal of Haematology</i> , 2006, 132, 317-325.	1.2	13
100	Aberrant Receptor-Mediated Endocytosis of <i>Schistosoma mansoni</i> Glycoproteins on Host Lipoproteins. <i>PLoS Medicine</i> , 2006, 3, e253.	3.9	33
101	Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 8804-8809.	3.3	80
102	Signaling through Mutants of the IgA Receptor CD89 and Consequences for Fc Receptor γ -Chain Interaction. <i>Journal of Immunology</i> , 2006, 176, 3603-3610.	0.4	40
103	The High-Affinity IgG Receptor, Fc γ RI, Plays a Central Role in Antibody Therapy of Experimental Melanoma. <i>Cancer Research</i> , 2006, 66, 1261-1264.	0.4	98
104	A novel human CD32 mAb blocks experimental immune haemolytic anaemia in Fc γ RIIIA transgenic mice. <i>British Journal of Haematology</i> , 2005, 130, 130-137.	1.2	20
105	Modulation of Fc γ RI (CD64) Ligand Binding by Blocking Peptides of Periplakin. <i>Journal of Biological Chemistry</i> , 2004, 279, 33875-33881.	1.6	24
106	Direct interaction between Fc γ RI (CD64) and periplakin controls receptor endocytosis and ligand binding capacity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 10392-10397.	3.3	49
107	Teasing apart structural determinants of 'toxicity' and 'adjuvanticity': implications for meningococcal vaccine development. <i>Journal of Endotoxin Research</i> , 2004, 10, 113-119.	2.5	30
108	CpG oligodeoxynucleotides enhance Fc γ RI-mediated cross presentation by dendritic cells. <i>International Immunology</i> , 2004, 16, 1091-1098.	1.8	15

#	ARTICLE	IF	CITATIONS
109	Flow cytometric determination of Fc γ RIIa (CD32) polymorphism. <i>Journal of Immunological Methods</i> , 2004, 294, 135-144.	0.6	13
110	Anti-GM1 IgG antibodies induce leukocyte effector functions via Fc γ receptors. <i>Annals of Neurology</i> , 2003, 53, 570-579.	2.8	26
111	Antibody-catalyzed water oxidation: state-of-the-art immunity or ancient history?. <i>Trends in Immunology</i> , 2003, 24, 467-469.	2.9	10
112	Role of Leukocyte Immunoglobulin G Receptors in Vaccine-Induced Immunity to <i>Streptococcus pneumoniae</i> . <i>Journal of Infectious Diseases</i> , 2003, 187, 1686-1693.	1.9	12
113	Central Role of Complement in Passive Protection by Human IgG1 and IgG2 Anti-pneumococcal Antibodies in Mice. <i>Journal of Immunology</i> , 2003, 170, 6158-6164.	0.4	68
114	Mac-1 (CD11b/CD18) as Accessory Molecule for Fc γ R (CD89) Binding of IgA. <i>Journal of Immunology</i> , 2002, 169, 3831-3836.	0.4	64
115	Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation. <i>Blood</i> , 2001, 97, 2478-2486.	0.6	189
116	Fc Receptor-Mediated Immunity Against <i>Bordetella pertussis</i> . <i>Journal of Immunology</i> , 2001, 167, 6545-6551.	0.4	55
117	Cytolytic Mechanisms and Expression of Activation-Regulating Receptors on Effector-Type CD8 ⁺ CD45RA ⁺ CD27 ⁺ Human T Cells. <i>Journal of Immunology</i> , 2000, 165, 1910-1917.	0.4	71
118	The Fc γ RIa (CD64) Ligand Binding Chain Triggers Major Histocompatibility Complex Class II Antigen Presentation Independently of Its Associated FcR β -Chain. <i>Blood</i> , 1999, 94, 808-817.	0.6	97
119	The alternatively spliced CD64 transcript Fc γ RIb2 does not specify a surface-expressed isoform. <i>European Journal of Immunology</i> , 1999, 29, 143-149.	1.6	20
120	Chronic bullous disease of childhood and a <i>paecilomyces</i> lung infection in chronic granulomatous disease. <i>Archives of Disease in Childhood</i> , 1997, 77, 150-152.	1.0	21
121	A novel polymorphism in the coding region of CYBB, the human gp91-phox gene. <i>Human Genetics</i> , 1996, 97, 611-613.	1.8	9
122	Interactions between the components of the human nadph oxidase: intrigues in the phox family. <i>Translational Research</i> , 1996, 128, 461-476.	2.4	107
123	Disturbed interaction of p21-rac with mutated p67-phox causes chronic granulomatous disease.. <i>Journal of Experimental Medicine</i> , 1996, 184, 1243-1249.	4.2	82
124	A novel polymorphism in the coding region of CYBB, the human gp91- phox gene. <i>Human Genetics</i> , 1996, 97, 611-613.	1.8	1
125	Interactions between the Cytosolic Components p47 and p67 of the Human Neutrophil NADPH Oxidase That Are Not Required for Activation in the Cell-free System. <i>Journal of Biological Chemistry</i> , 1995, 270, 11216-11221.	1.6	71
126	Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7